Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
184
Recruiting, any sponsor type, condition "chronic lymphocytic leukemia"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting184
- Completed1,222
184 trials
Showing 1 to 25, recently updated first.
- Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia PatientsRecruiting
Haikou Affiliated Hospital of Central South University Xiangya School of MedicineAcademic, hospital or other
NCT07763054 · 30 participants (planned) · Start Aug 1, 2025 · Primary completion Aug 31, 2026
Drug: Liposomal Amphotericin B · For: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome and 6 more
Sites: Hainan, China
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT03986034 · 75 participants (planned) · Start Jun 26, 2019 · Primary completion Nov 17, 2026
Drug: During Venetoclax · For: Chronic Lymphocytic Leukemia
Sites: Bethesda, Maryland
Fred Hutchinson Cancer CenterAcademic, hospital or other
NCT04195633 · 60 participants (planned) · Start Jan 25, 2021 · Primary completion Apr 15, 2027
Drug: Cyclophosphamide; Cyclosporine and 5 more · For: Acute Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia and 16 more
Sites: Seattle, Washington
National Cancer Institute (NCI)NIH
NCT04301076 · 30 participants (planned) · Start Aug 31, 2021 · Primary completion Jun 30, 2027
Drug: Cyclophosphamide; Doxorubicin Hydrochloride and 4 more · For: Acute Adult T-Cell Leukemia/Lymphoma; Adult T-Cell Leukemia/Lymphoma; Chronic Adult T-Cell Leukemia/Lymphoma and 1 more
Sites: Atlanta, Georgia; City of Saint Peters, Missouri; Creve Coeur, Missouri · 19 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04728893 · 490 participants (planned) · Start Apr 5, 2021 · Primary completion Jan 4, 2029
Drug: Nemtabrutinib · For: Hematologic Malignancies; Waldenstroms Macroglobulinaemia; Non-Hodgkins Lymphoma and 1 more
Sites: Springdale, Arkansas; La Jolla, California; Torrance, California · 121 sites in all
- A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05947851 · 735 participants (planned) · Start Aug 8, 2023 · Primary completion Jun 1, 2032
Drug: Nemtabrutinib; Venetoclax and 1 more · For: Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Chronic Lymphocytic; Small-Cell Lymphoma and 3 more
Sites: Springdale, Arkansas; Long Beach, California; Clermont, Florida · 107 sites in all
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT07428707 · 30 participants (planned) · Start Mar 11, 2026 · Primary completion Feb 1, 2030
Drug: Pirtobrutinib · For: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
Sites: Bethesda, Maryland
- A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06136559 · 1,200 participants (planned) · Start Dec 13, 2023 · Primary completion Sep 7, 2032
Drug: Nemtabrutinib; Ibrutinib and 1 more · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Mobile, Alabama; Gilbert, Arizona; Phoenix, Arizona · 206 sites in all
- ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLLPivotal-lookingRecruiting
Newave Pharmaceutical IncIndustry
NCT07342478 · 306 participants (planned) · Start Apr 23, 2026 · Primary completion Oct 30, 2029
Drug: Rocbrutinib; Pirtobrutinib · For: CLL / SLL; CLL (Chronic Lymphocytic Leukemia); CLL, Refractory and 5 more
Sites: Skokie, Illinois; Bethesda, Maryland; Las Vegas, Nevada · 10 sites in all
Nurix Therapeutics, Inc.Industry
NCT07221500 · 100 participants (planned) · Start Oct 15, 2025 · Primary completion Jan 2028
Drug: NX-5948 · For: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
Sites: Phoenix, Arizona; Duarte, California; Irvine, California · 47 sites in all
Nurix Therapeutics, Inc.Industry
NCT07520006 · 150 participants (planned) · Start Sep 30, 2026 · Primary completion May 2033
Drug: NX-5948; venetoclax and 2 more · For: B-cell Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Irvine, California; Aurora, Colorado; Coral Gables, Florida · 10 sites in all
Baylor College of MedicineAcademic, hospital or other
NCT06345027 · 78 participants (planned) · Start Apr 15, 2026 · Primary completion Jun 2029
Drug: Treatment Arm A · For: Leukemia, Myeloid, Acute; Leukemia, B-cell; Leukemia, T-Cell
Sites: Houston, Texas · 2 sites in all
Incyte Biosciences International SàrlIncyte (INCY)
NCT03934372 · 70 participants (planned) · Start Jan 29, 2020 · Primary completion Feb 1, 2028
Drug: Ponatinib · For: Acute Myeloid Leukemia; Accelerated Phase Chronic Myeloid Leukemia; Blast Phase Chronic Myeloid Leukemia and 6 more
Sites: Ghent, Belgium; Paris, France; Poitiers, France · 23 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07709000 · 60 participants (planned) · Start Oct 14, 2026 · Primary completion Nov 16, 2033
Drug: MK-1045; Acetaminophen (or similar antipyretic) and 5 more · For: Chronic Lymphocytic Leukaemia; Small Lymphocytic Lymphoma; Hematologic Malignancies
Sites: Medellín, Colombia; Bogotá, Colombia; Haifa, Israel · 10 sites in all
University of UtahAcademic, hospital or other
NCT04844528 · 86 participants (planned) · Start Feb 25, 2022 · Primary completion Aug 2027
Drug: Nicotinamide; Placebo · For: Chronic Lymphocytic Leukemia; Non-melanoma Skin Cancer (NMSC)
Sites: Salt Lake City, Utah
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT06967610 · 40 participants (planned) · Start Jul 15, 2025 · Primary completion Jun 1, 2031
Drug: Pirtobrutinib; Venetoclax and 1 more · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Leukemia (SLL)
Sites: Houston, Texas
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT06846671 · 250 participants (planned) · Start Apr 10, 2025 · Primary completion May 15, 2028
Drug: Tacabrutideg; Bendamustine and 3 more · For: CLL; Chronic Lymphocytic Leukemia; SLL
Sites: Jonesboro, Arkansas; Los Angeles, California; San Diego, California · 134 sites in all
- Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL StudyPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT04269902 · 247 participants (planned) · Start Mar 2, 2021 · Primary completion Oct 1, 2028
Drug: Obinutuzumab; Venetoclax · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 633 sites in all
Grifols Therapeutics LLCIndustry
NCT05645107 · 386 participants (planned) · Start Dec 26, 2022 · Primary completion Aug 2029
Drug: Xembify; Placebo · For: Hypogammaglobulinemia; Bacterial Infections; B-cell Chronic Lymphocytic Leukemia and 2 more
Sites: Bullhead City, Arizona; Huntington Park, California; St. Petersburg, Florida · 62 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT03263572 · 90 participants (planned) · Start Nov 29, 2017 · Primary completion Nov 30, 2027
Drug: Blinatumomab; Cytarabine and 2 more · For: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Acute Lymphoblastic Leukemia; BCR-ABL1 Fusion Protein Expression and 5 more
Sites: Houston, Texas
Kerry RogersAcademic, hospital or other
NCT07734038 · 155 participants (planned) · Start Sep 16, 2026 · Primary completion Dec 31, 2027
Drug: Venetoclax; Zanubrutinib · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Columbus, Ohio
City of Hope Medical CenterAcademic, hospital or other
NCT07582159 · 35 participants (planned) · Start Dec 19, 2026 · Primary completion Apr 14, 2029
Drug: Acalabrutinib; Tafasitamab and 1 more · For: Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Small Lymphocytic Lymphoma
Sites: Duarte, California; Irvine, California
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic LeukemiaPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05091424 · 332 participants (planned) · Start Mar 7, 2022 · Primary completion Feb 10, 2031
Drug: Mosunetuzumab; Tocilizumab and 2 more · For: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Sites: Rochester, Minnesota; New York, New York; Columbus, Ohio · 31 sites in all
- A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaPivotal-lookingRecruiting
Loxo Oncology, Inc.Eli Lilly (LLY)
NCT06588478 · 249 participants (planned) · Start Jan 3, 2025 · Primary completion Jun 2028
Drug: Pirtobrutinib · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Chandler, Arizona; Duarte, California; Irvine, California · 129 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT07218341 · 150 participants (planned) · Start Mar 9, 2026 · Primary completion May 2030
Drug: Pirtobrutinib; Idelalisib · For: Chronic Lymphocytic Leukemia; Lymphoma, Small Lymphocytic
Sites: Mobile, Alabama; Tucson, Arizona; Jacksonville, Florida · 50 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.